Ubiquitin‑specific peptidase 17 promotes cisplatin resistance via PI3K/AKT activation in non‑small cell lung cancer

Zhang,Shengchao; Xu,Zhenglang; Yuan,Jun; Chen,Hao

doi:10.3892/ol.2020.11568

Ubiquitin‑specific peptidase 17 promotes cisplatin resistance via PI3K/AKT activation in non‑small cell lung cancer

Authors:
- Shengchao Zhang
- Zhenglang Xu
- Jun Yuan
- Hao Chen
View Affiliations

Affiliations: Department of Thoracic Surgery, Qingpu Branch Zhongshan Hospital, Fudan University, Shanghai 201700, P.R. China
Published online on: April 23, 2020 https://doi.org/10.3892/ol.2020.11568
Pages: 67-74
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The suppression of ubiquitin-specific peptidase 17 (USP17) has previously been found to result in reduced tumorigenesis and invasion of non‑small cell lung cancer (NSCLC) cells. However, the functions and underlying mechanisms of USP17 in NSCLC progression remain unclear. In the present study, cisplatin treatment was found to upregulate USP17 expression in a dose‑dependent manner. Furthermore, USP17‑overexpressing (USP17‑OE) NSCLC A549 and H1299 cells were generated for mechanistic studies. The results from the Cell Counting Kit‑8 assay revealed increased cell proliferation in USP17‑OE cells compared with that of control cells. Moreover, the viability of USP17‑OE cells was significantly higher than that of the control cells, when treated with cisplatin. The results of the biochemical studies demonstrated enhanced PI3K and AKT phosphorylation in USP17‑OE NSCLC cells, whereas USP17‑knockdown decreased these levels of phosphorylation. By contrast, an AKT inhibitor abolished the USP17‑mediated enhancement of proliferation. Moreover, suppression of USP17 or the combination of the AKT inhibitor and cisplatin significantly reduced cell viability. Overall, the results of the present study suggest that PI3K/AKT activation is the underlying mechanism of USP17‑mediated cisplatin resistance in NSCLC.

View Figures

View References

1	Mao Y, Yang D and Krasna MJ: Epidemiology of lung cancer. Surg Oncol Clin N Am. 25:439–445. 2016. View Article : Google Scholar : PubMed/NCBI
2	Azar FE, Azami-Aghdash S, Pournaghi-Azar F, Mazdaki A, Rezapour A, Ebrahimi P and Yousefzadeh N: Cost-effectiveness of lung cancer screening and treatment methods: A systematic review of systematic reviews. BMC Health Serv Res. 17:4132017. View Article : Google Scholar : PubMed/NCBI
3	Jacobsen MM, Silverstein SC, Quinn M, Waterston LB, Thomas CA, Benneyan JC and Han PKJ: Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review. Lung Cancer. 112:156–164. 2017. View Article : Google Scholar : PubMed/NCBI
4	Giaccone G: Clinical perspectives on platinum resistance. Drugs. 59:9–37. 2000. View Article : Google Scholar : PubMed/NCBI
5	D'Andrea A and Pellman D: Deubiquitinating enzymes: A new class of biological regulators. Crit Rev Biochem Mol Biol. 33:337–352. 1998. View Article : Google Scholar : PubMed/NCBI
6	Weathington NM and Mallampalli RK: Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest. 124:6–12. 2014. View Article : Google Scholar : PubMed/NCBI
7	Welchman RL, Gordon C and Mayer RJ: Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol. 6:599–609. 2005. View Article : Google Scholar : PubMed/NCBI
8	Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK and Bernards R: A genomic and functional inventory of deubiquitinating enzymes. Cell. 123:773–786. 2005. View Article : Google Scholar : PubMed/NCBI
9	Song H, Tao L, Chen C, Pan L, Hao J, Ni Y, Li D, Li B and Shi G: USP17-mediated deubiquitination and stabilization of HDAC2 in cigarette smoke extract-induced inflammation. Int J Clin Exp Pathol. 8:10707–10715. 2015.PubMed/NCBI
10	de la Vega M, Kelvin AA, Dunican DJ, McFarlane C, Burrows JF, Jaworski J, Stevenson NJ, Dib K, Rappoport JZ, Scott CJ, et al: The deubiquitinating enzyme USP17 is essential for GTPase subcellular localization and cell motility. Nat Commun. 2:2592011. View Article : Google Scholar : PubMed/NCBI
11	Han L, Yang J, Wang X, Wu Q, Yin S, Li Z, Zhang J, Xing Y, Chen Z, Tsun A, et al: The E3 deubiquitinase USP17 is a positive regulator of retinoic acid-related orphan nuclear receptor γt (RORγt) in Th17 cells. J Biol Chem. 289:25546–25555. 2014. View Article : Google Scholar : PubMed/NCBI
12	Borbely G, Haldosen LA, Dahlman-Wright K and Zhao C: Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells. Oncotarget. 6:33623–33635. 2015. View Article : Google Scholar : PubMed/NCBI
13	Hu M, Chen H, Han C, Lan J, Xu Y, Li C, Xue Y and Lou M: Expression and functional implications of USP17 in glioma. Neurosci Lett. 616:125–131. 2016. View Article : Google Scholar : PubMed/NCBI
14	McFarlane C, Kelvin AA, de la Vega M, Govender U, Scott CJ, Burrows JF and Johnston JA: The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression. Cancer Res. 70:3329–3339. 2010. View Article : Google Scholar : PubMed/NCBI
15	McCann AP, Smyth P, Cogo F, McDaid WJ, Jiang L, Lin J, Evergren E, Burden RE, Van Schaeybroeck S, Scott CJ and Burrows JF: USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells. Cell Commun Signal. 16:772018. View Article : Google Scholar : PubMed/NCBI
16	McFarlane C, McFarlane S, Paul I, Arthur K, Scheaff M, Kerr K, Stevenson M, Fennell DA and Johnston JA: The deubiquitinating enzyme USP17 is associated with non-small cell lung cancer (NSCLC) recurrence and metastasis. Oncotarget. 4:1836–1843. 2013. View Article : Google Scholar : PubMed/NCBI
17	Zhang S, Yuan J and Zheng R: Suppression of Ubiquitin-Specific Peptidase 17 (USP17) inhibits tumorigenesis and invasion in non-small cell lung cancer cells. Oncol Res. 24:263–269. 2016. View Article : Google Scholar : PubMed/NCBI
18	Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, et al: Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem. 275:24500–24505. 2000. View Article : Google Scholar : PubMed/NCBI
19	Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT and Smyrk TC: AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis. 23:201–205. 2002. View Article : Google Scholar : PubMed/NCBI
20	Saini MK and Sanyal SN: PTEN regulates apoptotic cell death through PI3-K/Akt/GSK3β signaling pathway in DMH induced early colon carcinogenesis in rat. Exp Mol Pathol. 93:135–146. 2012. View Article : Google Scholar : PubMed/NCBI
21	Xue G, Restuccia DF, Lan Q, Hynx D, Dirnhofer S, Hess D, Ruegg C and Hemmings BA: Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-β signaling axes. Cancer Discov. 2:248–259. 2012. View Article : Google Scholar : PubMed/NCBI
22	Li Y, Yang Q, Guan H, Shi B, Ji M and Hou P: ZNF677 suppresses Akt phosphorylation and tumorigenesis in thyroid cancer. Cancer Res. 78:5216–5228. 2018. View Article : Google Scholar : PubMed/NCBI
23	Tang Y, Xiao G, Chen Y and Deng Y: LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling. Anticancer Drugs. 29:725–735. 2018.PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Malkomes P, Lunger I, Luetticke A, Oppermann E, Haetscher N, Serve H, Holzer K, Bechstein WO and Rieger MA: Selective AKT Inhibition by MK-2206 represses colorectal cancer-initiating stem cells. Ann Surg Oncol. 23:2849–2857. 2016. View Article : Google Scholar : PubMed/NCBI
26	Wisinski KB, Tevaarwerk AJ, Burkard ME, Rampurwala M, Eickhoff J, Bell MC, Kolesar JM, Flynn C and Liu G: Phase I Study of an AKT Inhibitor (MK-2206) combined with lapatinib in adult solid tumors followed by dose expansion in advanced HER2+ breast cancer. Clin Cancer Res. 22:2659–2667. 2016. View Article : Google Scholar : PubMed/NCBI
27	Agarwal E, Chaudhuri A, Leiphrakpam PD, Haferbier KL, Brattain MG and Chowdhury S: Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer. BMC Cancer. 14:1452014. View Article : Google Scholar : PubMed/NCBI
28	Baek KH: Cytokine-regulated protein degradation by the ubiquitination system. Curr Protein Pept Sci. 7:171–177. 2006. View Article : Google Scholar : PubMed/NCBI
29	Shin JM, Yoo KJ, Kim MS, Kim D and Baek KH: Hyaluronan- and RNA-binding deubiquitinating enzymes of USP17 family members associated with cell viability. BMC Genomics. 7:2922006. View Article : Google Scholar : PubMed/NCBI
30	Burrows JF, Kelvin AA, McFarlane C, Burden RE, McGrattan MJ, De la Vega M, Govender U, Quinn DJ, Dib K, Gadina M, et al: USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity. J Biol Chem. 284:9587–9595. 2009. View Article : Google Scholar : PubMed/NCBI
31	Song C, Liu W and Li J: USP17 is upregulated in osteosarcoma and promotes cell proliferation, metastasis, and epithelial-mesenchymal transition through stabilizing SMAD4. Tumour Biol. 39:10104283177171382017. View Article : Google Scholar : PubMed/NCBI
32	Wang M, He SF, Liu LL, Sun XX, Yang F, Ge Q, Wong WK and Meng JY: Potential role of ZEB1 as a DNA repair regulator in colorectal cancer cells revealed by cancer-associated promoter profiling. Oncol Rep. 38:1941–1948. 2017. View Article : Google Scholar : PubMed/NCBI
33	Kim J, D'Annibale S, Magliozzi R, Low TY, Jansen P, Shaltiel IA, Mohammed S, Heck AJ, Medema RH and Guardavaccaro D: USP17- and SCFβTrCP-regulated degradation of DEC1 controls the DNA damage response. Mol Cell Biol. 34:4177–4185. 2014. View Article : Google Scholar : PubMed/NCBI
34	Zhu J, Sun Y, Lu Y, Jiang X, Ma B, Yu L, Zhang J, Dong X and Zhang Q: Glaucocalyxin A exerts anticancer effect on osteosarcoma by inhibiting GLI1 nuclear translocation via regulating PI3K/Akt pathway. Cell Death Dis. 9:7082018. View Article : Google Scholar : PubMed/NCBI
35	Koundouros N and Poulogiannis G: Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer. Front Oncol. 8:1602018. View Article : Google Scholar : PubMed/NCBI
36	Zheng J, Zhang M, Zhang L, Ding X, Li W and Lu S: HSPC159 promotes proliferation and metastasis by inducing epithelial-mesenchymal transition and activating the PI3K/Akt pathway in breast cancer. Cancer Sci. 109:2153–2163. 2018. View Article : Google Scholar : PubMed/NCBI
37	Zhong C, Chen Y, Tao B, Peng L, Peng T, Yang X, Xia X and Chen L: LIM and SH3 protein 1 regulates cell growth and chemosensitivity of human glioblastoma via the PI3K/AKT pathway. BMC Cancer. 18:7222018. View Article : Google Scholar : PubMed/NCBI
38	Gong T, Cui L, Wang H, Wang H and Han N: Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway. J Transl Med. 16:1642018. View Article : Google Scholar : PubMed/NCBI
39	O'Reilly D, Johnson P and Buchanan PJ: Hypoxia induced cancer stem cell enrichment promotes resistance to androgen deprivation therapy in prostate cancer. Steroids. 152:1084972019. View Article : Google Scholar : PubMed/NCBI
40	Liu W, Yu WM, Zhang J, Chan RJ, Loh ML, Zhang Z, Bunting KD and Qu CK: Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations. Leukemia. 31:1415–1422. 2017. View Article : Google Scholar : PubMed/NCBI
41	Wang L, Cao XX, Chen Q, Zhu TF, Zhu HG and Zheng L: DIXDC1 targets p21 and cyclin D1 via PI3K pathway activation to promote colon cancer cell proliferation. Cancer Sci. 100:1801–1808. 2009. View Article : Google Scholar : PubMed/NCBI
42	Zhao W, Sun Q, Yu Z, Mao S, Jin Y, Li J, Jiang Z, Zhang Y, Chen M, Chen P, et al: MiR-320a-3p/ELF3 axis regulates cell metastasis and invasion in non-small cell lung cancer via PI3K/Akt pathway. Gene. 670:31–37. 2018. View Article : Google Scholar : PubMed/NCBI
43	Zhao J, Xu J and Zhang R: SRPX2 regulates colon cancer cell metabolism by miR-192/215 via PI3K-Akt. Am J Transl Res. 10:483–490. 2018.PubMed/NCBI
44	Zhang B, Liu L, Guan H, Wang H, Zhang Z and Zhou P: HepG2 cell cycle related gene transcriptional profiles are altered by a novel vanillin derivative BVAN08. J Med Discov. 2:170362017. View Article : Google Scholar
45	Deng N and Chen Y: Application of CRISPR-Cas9 gene editing system: Non-viral delivery strategies and improvements. J Med Discov. 3:170572018.